GlassScriptPhysician profile
Monay A Link
NPI 1285092742
$6,402.01
in general payments reported to CMS, 2019-2025
56 companies · $898 in 2025
The $898 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $498 · 2022: $779 · 2023: $1,310 · 2024: $2,917 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,867 · Education: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,866.74 |
| Education | $258.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,195.66 | 2021-2025 | Darzalex, Tecvayli, Rybrevant |
| Novartis Pharmaceuticals Corporation | $559.39 | 2022-2025 | |
| Celgene Corporation | $413.82 | 2022-2024 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $388.82 | 2021-2024 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $261.88 | 2021-2025 | Padcev, Vyloy |
| Lilly USA, LLC | $213.60 | 2023-2024 | Jaypirca, Verzenio |
| E.R. Squibb & Sons, L.L.C. | $202.99 | 2021-2025 | Opdivo, Opdualag |
| Eisai INC. | $199.43 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $195.96 | 2023-2024 | Fruzaqla, Iclusig, Alunbrig |
| Astrazeneca Pharmaceuticals LP | $176.21 | 2021-2024 | Imfinzi, Lynparza |
| Sobi, INC | $162.78 | 2024 | |
| Gilead Sciences, INC. | $158.85 | 2022-2025 | Trodelvy |
| Morphosys, US INC. | $154.48 | 2022-2023 | Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $152.93 | 2021-2024 | |
| Genzyme Corporation | $143.49 | 2022-2025 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monay Link listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.